Edward Nash
Stock Analyst at Canaccord Genuity
(3.44)
# 1,535
Out of 4,479 analysts
55
Total ratings
46.51%
Success rate
5.11%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Buy | $35 | $15.51 | +125.66% | 5 | Jun 27, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $2.00 | +300.00% | 3 | May 23, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $59 → $56 | $23.16 | +141.80% | 4 | May 13, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $15 → $18 | $8.28 | +117.39% | 6 | May 7, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $2.92 | +586.11% | 2 | Apr 8, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $21 → $9 | $3.82 | +135.60% | 1 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $338 → $377 | $279.31 | +34.98% | 6 | Mar 15, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $16 → $15 | $2.26 | +563.72% | 5 | Mar 13, 2024 | |
| MORF Morphic Holding | Maintains: Buy | $68 → $66 | $32.55 | +102.76% | 2 | Mar 8, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $37 → $38 | $32.67 | +16.31% | 3 | Dec 13, 2023 | |
| THTX Theratechnologies | Assumes: Hold | $8 | $1.40 | +473.48% | 3 | Jul 3, 2023 | |
| RZLT Rezolute | Maintains: Buy | $16 → $17 | $4.31 | +294.43% | 2 | May 19, 2023 | |
| PLRX Pliant Therapeutics | Initiates: Buy | $48 | $10.86 | +341.99% | 1 | May 18, 2023 | |
| ORMP Oramed Pharmaceuticals | Maintains: Hold | $3 → $2 | $2.56 | -21.88% | 3 | May 17, 2023 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | $75 → $15 | $0.29 | +5,144.76% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Maintains: Hold | $120 → $80 | $6.97 | +1,047.78% | 3 | Sep 13, 2019 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | n/a | $41.12 | - | 3 | Oct 29, 2018 | |
| QURE uniQure | Initiates: Buy | n/a | $4.45 | - | 1 | May 24, 2018 | |
| ABEO Abeona Therapeutics | Initiates: Buy | n/a | $4.20 | - | 1 | Nov 8, 2017 |
Verona Pharma
Jun 27, 2024
Maintains: Buy
Price Target: $35
Current: $15.51
Upside: +125.66%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $2.00
Upside: +300.00%
Akero Therapeutics
May 13, 2024
Maintains: Buy
Price Target: $59 → $56
Current: $23.16
Upside: +141.80%
Travere Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $8.28
Upside: +117.39%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $2.92
Upside: +586.11%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21 → $9
Current: $3.82
Upside: +135.60%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $279.31
Upside: +34.98%
Ventyx Biosciences
Mar 13, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.26
Upside: +563.72%
Morphic Holding
Mar 8, 2024
Maintains: Buy
Price Target: $68 → $66
Current: $32.55
Upside: +102.76%
Corcept Therapeutics
Dec 13, 2023
Maintains: Buy
Price Target: $37 → $38
Current: $32.67
Upside: +16.31%
Theratechnologies
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.40
Upside: +473.48%
Rezolute
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $4.31
Upside: +294.43%
Pliant Therapeutics
May 18, 2023
Initiates: Buy
Price Target: $48
Current: $10.86
Upside: +341.99%
Oramed Pharmaceuticals
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.56
Upside: -21.88%
Galmed Pharmaceuticals
Aug 8, 2022
Downgrades: Hold
Price Target: $75 → $15
Current: $0.29
Upside: +5,144.76%
Adverum Biotechnologies
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $6.97
Upside: +1,047.78%
Ultragenyx Pharmaceutical
Oct 29, 2018
Maintains: Buy
Price Target: n/a
Current: $41.12
Upside: -
uniQure
May 24, 2018
Initiates: Buy
Price Target: n/a
Current: $4.45
Upside: -
Abeona Therapeutics
Nov 8, 2017
Initiates: Buy
Price Target: n/a
Current: $4.20
Upside: -